• Implementation
  • Manufacturing
  • Measles
  • Rubella
  • Microarray Patch
2021 — 2022

Develop an initial value assessment for measles-rubella microarray patches


Assessing public and private sector perspectives to identify solutions to roadblocks preventing the development and implementation of the measles-rubella microarray patch in low- and middle-income countries.

Image Credit: Bill Wegener on Unsplash
  • Focus Project
  • To develop an initial full vaccine value assessment for the measles-rubella microarray patch (MR-MAPs) from different stake holder perspectives, to identify and remove potential challenges.
MMGH conducted a preliminary value assessment to quantify the potential cost of developing, and impact of introducing, MR-MAPs. The analysis included a quantitative assessment of public health needs, market and pricing analyses, and analyses of discounted cash flow, impact, and cost effectiveness. The assessment also identified potential roadblocks to the acceptance and implementation of the patch in low- and middle-income countries. MMGH consulted with various stakeholders from the public health and private sector, as well as country level. This project was done in partnership with the London School of Hygiene and Tropical Medicine, who conducted the impact and cost effectiveness analyses, and Global Health Visions who supported the creation of communication materials.

The report was accepted by key public health stakeholders responsible for taking forward the development and implementation of microarray patches, and aimed to identify potential areas of risk and mitigating actions.

Focus Area
Policy & Strategy
Project Outputs
Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation
Estimating the future global dose demand for Measles-Rubella microarray patches